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Abstract  1 
 2 
This study reports the susceptibility to antimicrobial agents of staphylococci 3 
(n=105) isolated from dogs, and the factors associated with this resistance. The study 4 
animals were 23 healthy dogs (group A), 24 with first-time pyoderma (group B), and 27 5 
with recurrent pyoderma that had undergone long-term antibiotic treatment (group C). 6 
Staphylococci were more commonly isolated from the pyoderma-affected than the 7 
healthy dogs (p<0.0001).    8 
 9 
Some 78% of the isolates were resistant to at least one antimicrobial agent. 10 
Resistance to amoxicillin-clavulanate,cephalosporins (OR 4.29, 95% CI [1.15, 16.3] 11 
respectively), enrofloxacin (OR 9.47, 95% CI [1.53, 58.5]) and ciprofloxacin (OR 79.7 12 
95% CI [3.26, 1947.4]) was more common among group C isolates. Some 32% of all 13 
the isolates were multiresistant (MR) and 10.4% were methicillin-resistant (MRS). The 14 
probability of isolating MRS staphylococci in group C increased by a factor of four 15 
(95% CI [1.18, 17.9]) compared to A plus B. Multi-resistant (MR) isolates were 16 
obtained more commonly from urban than rural dogs (OR 3.79, 95% CI [1.09, 13.17]).  17 
All the MRS staphylococci encountered were obtained from urban dogs and more 18 
commonly from male dogs (p= 0.07). 19 
 20 
This study shows that dogs bred in urban habitat, with a history of antibiotic 21 
therapy in the past year represents significant risk of being carriers of isolates resistant 22 
to methicillin (MRS) and other antimicrobials. These factors should be considered 23 
before applying an antimicrobial treatment in veterinary clinics. 24 
 25 
Keywords 26 
Staphylococci, pyoderma, dog, antimicrobial susceptibility, methicillin-27 
resistance  28 
 29 
1. Introduction 30 
 31 
Staphylococcal skin infections are one of the most common reasons why animal 32 
owners seek the help of their veterinarians.  The coagulase-positive staphylococci most 33 
































S. intermedius and S. schleiferi spp. coagulans (Quinn et al., 1998; Shimizu et al., 2001; 1 
Morris et al., 2006; Fazakerley et al., 2009).  The high degree of genetic similarity 2 
shown by the first two of these species has led to their reclassification as a single, 3 
genetically homogeneous group known as the Staphylococcus intermedius group (SIG).    4 
(Sasaki et al., 2007; Fitzgerald, 2009).  Other coagulase-positive and coagulase-negative 5 
staphylococci (CoNS) have also been isolated from dogs with pyoderma (Zdovc et al., 6 
2004; Hauschild and Wójcik, 2007). 7 
 8 
The control of canine pyoderma is based on local or systemic antimicrobial 9 
therapy (Ganiere et al., 2005).  However, recent years have seen a worldwide increase in 10 
the prevalence of resistance to commonly-used antimicrobial agents (Petersen et al., 11 
2002; Kadlec et al., 2010). Of particular importance are methicillin-resistant strains 12 
(MRS) since they are resistant to all β-lactams antibiotics, commonly used in oral 13 
treatment of pyoderma. Also, animals can become reservoirs of such strains for humans, 14 
so they have a major impact on public health (Guardabassi et al., 2004; Loeffler et al., 15 
2007; Fitzgerald, 2009). Resistance to methicillin is conferred by an altered penicillin-16 
binding protein (PBP)2a, encoded by the mecA gene, which is located on a mobile 17 
genetic element designated staphylococcal cassette chromosome (SCCmec) (Matsuhashi 18 
et al., 1986). 19 
 20 
A number of authors report differences in the resistance patterns between isolates 21 
(Holm et al., 2002; Hartmann et al., 2005; Futagawa-Saito et al., 2007); studies are 22 
therefore needed that determine the risk factors associated with resistance. The aim of 23 
the present work was to determine the antimicrobial susceptibility of staphylococci 24 
isolated from dogs presenting at the Clinical Veterinary Hospital of Cordoba University 25 
(Spain), and to determine the possible risk factors associated with resistance. Such 26 
knowledge should allow for the better control of canine pyoderma. 27 
 28 
Material and methods 29 
 30 
Animals and sample collection 31 
The study animals were 74 dogs admitted to the Clinical Veterinary Hospital of 32 
Cordoba from October to December 2009 (Table 1). Three groups were established; 33 
































group C with 27 dogs presenting with recurrent pyoderma even though they had 1 
received long-term antibiotic treatments.  The animals belonging to the first two groups 2 
had not received antibiotic therapy in the preceding year. Two reasons led us to select 3 
this time period: One year was a period of time that included all seasons, and also, all 4 
owners could confidently remember if their dogs had received any prior therapy during 5 
that time. The most common primary causes of chronic pyoderma in group C were 6 
atopic dermatitis, endocrine dermatoses and primary pyoderma. In this group, antibiotic 7 
treatment was ended at least two weeks before samples were taken. The following data 8 
were collected for each animal: sex, age, habitat, and details of cohabitation with other 9 
dogs, site of isolation and treatment history (Table 4). 10 
 11 
Swabs for bacterial culture and transport (Culturette swabs with Amies 12 
Transport medium [EUROTUBO
®
], Deltalab) were taken from different body areas: the 13 
mouth mucosa and perineum in healthy animals, and the lesion zone and perineum in 14 
animals with pyoderma (Hartmann et al., 2005; Griffeth et al., 2008; Fazakerley et al., 15 
2009). Swabs were rubbed vigorously against the sampling site for 5 s and processed 16 
immediately. 17 
 18 
Bacterial isolation and identification 19 
All swabs were grown on Blood Agar (Oxoid SA, Spain) supplemented with 5% 20 
sterile, defibrinated sheep’s blood (Oxoid S.A., Spain) and Mannitol Salt Agar (Oxoid 21 
S.A., Spain). All plates were incubated aerobically at 37ºC for 18 to 24 h.  Isolates were 22 
identified on the basis of colony morphology, Gram staining, pigment production and 23 
haemolysis. All Gram-positive, catalase-positive cocci with colony morphology 24 
compatible with that of Staphylococcus species were selected for further analysis. 25 
Coagulase activity was determined via the tube coagulase test using rabbit serum (Difco 26 
S.A., Spain) and the clumping factor test (Oxoid S.A., Spain). Coagulase-positive 27 
isolates were further identified by conventional biochemical tests: acetoin production 28 
(Vogues Proskauer), acid production from lactose, the trehalose test, the beta-29 
galactosidase test (ONPG test), and susceptibility to polymyxin B and furazolidone, as 30 
previously described (Zdoc et al., 2004; Sasaki et al., 2007). Coagulase-negative 31 
isolates were identified using the API 20 STAPH system (bioMerieux S.A., Spain) 32 

































Susceptibility tests  1 
The antimicrobial susceptibility of the isolates was determined on Mueller-Hinton 2 
agar (Oxoid, Spain) using the disk diffusion method. Eight different groups of 3 
antimicrobial agents, widely used in companion animal clinical, were studied: beta 4 
lactams (represented by ampicillin [10 µg/disk]), amoxicillin-clavulanate (20 and 10 5 
µg/disk), cephalothin (30 µg/disk), cephalexin (30 µg/disk), cephadroxyl (30 µg/disk) 6 
and ceftiofur (30 µg/disk). Fluoroquinolones were represented by ciprofloxacin (5 7 
µg/disk) and enrofloxacin (5 µg/disk). Macrolides and lincosamides were represented 8 
by erythromycin (15 µg/disk) and clindamycin (2 µg/disk): erythromycin and 9 
clindamycin discs were placed approximately 15 mm apart to detect MLSBi resistance. 10 
Tetracycline (30 µg/disk), gentamicin (10 µg/disk), and rifampin (5 µg/disk) were also 11 
tested. All antimicrobial agents were purchased from Oxoid (Oxoid, S.A., Spain). 12 
Staphylococcus aureus reference strain ATCC 25923 was used as a quality control. The 13 
measurement and interpretation of growth inhibition diameters was performed 14 
following the CLSI guidelines for veterinary antimicrobial susceptibility tests for 15 
pathogens of animal origin (CLSI, 2008). Quality control was performed for each day of 16 
testing or weekly if satisfactory performance was documented and whenever a new lot 17 
of media or lot of disk were used, as recommended the CLSI (2008). In this work, 18 
isolates with resistance to three or more classes of antimicrobial agents were considered 19 
multiresistant (MR), following the criteria of Holm et al (2002).  20 
All 105 isolates were tested for β-lactamase production with nitrocefin disk 21 
(Oxoid, S.A., Spain) according to the manufacturer's instructions. Development of a red 22 
colour indicated positive results. Those beta-lactamase producing isolates were 23 
considered resistant to ampicillin. 24 
Resistance to oxacillin was determined by the growth of blue colonies in the 25 
selective medium Oxacillin Resistance Screening Agar Base (ORSAB, Oxoid S.A., 26 
Spain), supplemented with polymyxin B (50 IU/L) and oxacillin (2 mg/L), after 24-48 h 27 
aerobic incubation at 37ºC.  Reference quality control strains of oxacillin-resistant S. 28 
aureus (ATCC 43300), oxacillin-susceptible S. aureus (ATCC 25923) were used for 29 
screening for methicillin-resistant isolates. Suspected MRS isolates were further 30 
confirmed by the latex agglutination assay (Oxoid, S.A., Spain), following the 31 
manufacturer's recommendations. 32 
 33 
































A total of 105 staphylococci was collected (table 1). This allowed the 1 
comparison of resistance to antimicrobial agents between the study groups (95% 2 
confidence and 80% power), with a minimum OR of 2, for an expected proportion of 3 
multiresistant isolates in pyoderma-affected dogs of 30% (Holm et al., 2002). 4 
Staphylococcal species distribution was examined by calculating the frequency of 5 
isolation of the different species in each group, which were then compared using the 6 


test. For the study of the risk factors associated with antimicrobial resistance, 7 
multiresistance (MR) and methicillin resistance (MRS), the percentage of resistant 8 
isolates in each group and their 95% confidence intervals (95% CI) were determined 9 
and compared using Fisher’s exact test and via the calculation of odds ratios (OR). 10 
Significance was set at p<0.05. All statistical analyses were performed using SPSS 11 




Staphylococcal species distribution 16 
Table 1 shows that staphylococci were recovered from 67 of the 74 (90.5%) 17 
studied animals: from 16 (69.5%) healthy dogs (group A), from 24 (100%) dogs with 18 
first-time pyoderma (group B), and from 27 (100%) of the dogs with recurrent 19 
pyoderma (group C). Two corporal zones were studied from each animal; when various 20 
isolates belonged to the same species and similar susceptibility were obtained from an 21 
individual dog, only one isolate was considered to avoid duplicate results. 22 
 23 
A total of 105 staphylococcus isolates were obtained (Table 1). Twenty-one 24 
(20%) isolates were obtained from group A animals, 40 (38%) from group B animals, 25 
and 44 (42%) from group C animals. The frequency of isolation of staphylococci was 26 
significantly higher (p<0.0001) in the pyoderma-affected dogs (groups B and C) than in 27 
the healthy dogs (group A).  28 
 29 
 Table 1 also shows that the majority of the isolates (83; 79%) were SIG 30 
members. Ten (9.5%) isolates were identified as S. aureus and 12 (11.4%) as different 31 
CoNS. The frequency of isolation of SIG members and CoNS was statistically higher in 32 
pyoderma-affected animals (p<0.05).  No differences were observed among groups in 33 

































Antimicrobial susceptibility 2 
Table 2 summarises the frequency of antimicrobial resistance. Resistance was 3 
most commonly seen against ampicillin (68.6%), tetracycline (41%), erythromycin 4 
(35.2%) and clindamycin (28.6%).  5 
 6 
The frequency of isolates resistant to erythromycin and clindamycin was very 7 
similar among groups, but the frequency of isolates resistant to tetracycline was 8 
significantly greater in the pyoderma-affected animals (groups B and C) (Table 2) 9 
(tetracycline: OR B/A groups 3.84, 95% CI [1.09-13.4]); OR C/A groups 3.54, 95% CI 10 
[1.02-12.2]). No differences were observed between groups B and C (p>0.05). 11 
 12 
Large differences were also observed between the isolates obtained from group 13 
C animals compared to A plus B animals in terms of resistance to cephalosporins and 14 
amoxicillin-clavulanate (OR 4.29, 95% CI [1.15, 16.3]), enrofloxacin (OR 9.47, 95% CI 15 
[1.53, 58.5]) and ciprofloxacin (OR 79.7 95% CI [3.26, 1947.4]).  16 
 17 
Table 3 shows the resistance pattern detected and the frequency of MSS and 18 
MRS isolates. A total of 82 of the staphylococci isolated (78.1%) were resistant to at 19 
least one antimicrobial agent, i.e., 14 of the 21 isolates (66.6%) obtained from animals 20 
of group A, 30 of the 40 isolates (75%) from the dogs in group B, and 38 of the 44 21 
isolates (86.4%) of the group C animals. Statistical analysis (Table 4) showed no 22 
differences between treated and not-treated groups (p = 0.08), although a clear trend to 23 
resistance to one or more antimicrobials was observed among isolates obtained from 24 
animals with a history of antibiotic therapy.  25 
 26 
Thirty-four (32.3%) of the 105 isolates were resistant to three or more 27 
antimicrobial agents (Table 3), and were considered multiresistant (6 isolates obtained 28 
from animals in group A, 13 isolates recovered from group B, and 15 from group C; 29 
however, these differences were not significant (p>0.05).  Eleven (10.4%) isolates were 30 
resistant to methicillin (7/105 identified as SIG, 2/105 as S. aureus, 1/105 as S. cohnii 31 
subsp. cohnii and 1/105 as S. capitis). All isolates produced the protein PBP2a in the 32 
latex agglutination test. All the MRS isolates came from pyoderma-affected animals 33 
































long-term treatments and the presence of MRS staphylococci (18.2% of MRS isolates in 1 
group C vs. 7.5% in A plus B animals; OR 4.3, 95% CI [1.15, 15.9]) (Table 4). Among 2 
the MRS isolates, 7 (63.6%) were also resistant to tetracycline, 3 (87.3%) to 3 
fluoroquinolones (ciprofloxacin and enrofloxacin), erythromycin and clindamycin, 4 
respectively, and 2 (18.2%) to gentamicin. One (9.1%) of the MR isolates was also 5 
resistant to rifampin. 6 
 7 
Statistical analysis was performed to determine possible risk factors associated 8 
with the isolation of multidrug resistant (MR) and methicillin resistant (MRS), 9 
respectively (Table 4). MR isolates were obtained more commonly from urban than 10 
rural dogs (OR 3.79; 95% CI [1.09, 13.17]).  However, no correlation was found 11 
between the multiresistance and sex, age, previous treatments of the animals (Table 4).  12 
All MRS staphylococci were obtained from urban dogs (11.2% versus 0%, p = 0.19) 13 
and a more frequently from males (14.9% versus 3.7%, p = 0.07)  14 
 15 
The assessment of MLSBi resistance showed 29 (27.6%) of the 105 isolates to 16 
be resistant to erythromycin and clindamycin. Sixteen isolates showed an unusual 17 
pattern in the Kirby-Bauer test (ERY-resistant but CLI-susceptible). The results of the 18 
D-test showed three phenotypes: 2/16 isolates showed a clindamycin-inducible 19 
resistance phenotype (D-zone effect), 7/16 showed a negative phenotype (ERY-resistant 20 





The present results highlight the large number of apparently healthy dogs that 26 
are carriers of staphylococci on their skin and mucosae (69.5%). This proportion 27 
increases significantly in animals with pyoderma (to 100%), as described by other 28 
authors (Hartmann et al., 2005; Fatagawa-Saito et al., 2007). The results of the 29 
biochemical tests showed the majority (83/105, 79%) of isolates to be SIG members 30 
(Table 1), with the frequency of isolation increasing significantly in pyoderma-affected 31 
animals (p<0.05). S. aureus and CoNS (9.5% and 11.4% respectively) were also 32 
isolated in all three groups of animals with a similar trend. S. aureus has traditionally 33 
































transient inhabitant that has the potential to cause disease; it is thought to be involved in 1 
<5% of skin infections (Holm et al., 2002; Hauschild and Wojcik, 2007; Fazakerley et 2 
al., 2009). However, in the present work, although its frequency was low, most isolates 3 
(70%) were obtained from areas of skin with lesions.  The low frequency of isolation of 4 
CoNS should be noted, although recent studies indicate the emergence of these species’ 5 
involvement in canine pyoderma and otitis (Hauschild and Wójcik, 2007). 6 
 7 
The results of the in vitro susceptibility studies show the effectiveness of the 8 
different groups of antimicrobial agents examined (Table 2), and confirm the results of 9 
previous authors who report cephalosporins, fluoroquinolones, amoxicillin/clavulanic 10 
acid, gentamicin and rifampin to be first-line choices in staphylococcus-induced canine 11 
pyoderma (Morris et al., 2006; Vanni et al., 2009). In the present work, a high 12 
proportion of isolates were resistant to ampicillin (68.6%), tetracycline (41%), 13 
erythromycin (35.2%) and clindamycin (28.6%).  Results from other countries show 14 
there to be wide variation in terms of bacterial resistance profiles, but in general the 15 
above agents are less effective for the empirical treatment of canine pyoderma (Holm et 16 
al., 2002; Ganiere et al., 2005; Hartmann et al., 2005; Fatagawa-Saito et al., 2007; 17 
Hauschild and Wójcik, 2007).  18 
 19 
In the present study, 78% of the isolates were resistant to at least one 20 
antimicrobial agent. The isolates obtained from the group B and C animals were 21 
resistant to more antimicrobial agents than those obtained from the healthy dogs (group 22 
A) (Table 2), with significant differences for tetracycline. The frequency of isolates 23 
resistant to different antimicrobial agents increased when the animals had recurrent 24 
pyoderma and received long-term antibiotic treatments, significantly so for 25 
cephalosporins and amoxicillin-clavulanate (OR 4.29, 95% CI [1.15, 16.3]), 26 
enrofloxacin (OR 9.47, 95% CI [1.53, 58.5]) and ciprofloxacin (OR 79.7 95% CI [3.26, 27 
1947.4]).  28 
 29 
The acquisition of resistance to fluoroquinolones has been described in animals 30 
with recurrent pyoderma when treated with this group of antimicrobial agents (Ganière 31 
et al., 2001). In the present work, most of the group C animals had been treated with 32 
amoxicillin-clavulanate, cefalexin and ciprofloxacin (data not shown); significant 33 
































These results suggest that a microbiological study is always advisable in clinical 1 
recurrent pyoderma despite the effectiveness generally shown by amoxicillin-2 
clavulanate and cephalosporins (Rantala et al., 2004). 3 
 4 
More than 30% of the isolates detected were multiresistant (Table 3), as 5 
described by other authors (Holm et al., 2002; Ganiere et al., 2005). However, in 6 
contrast to these studies, no significant difference (p>0.05) was seen (table 4) in the 7 
number of MR isolates in each group despite the larger number associated with group C 8 
(45.6%). A total of 23 resistance pattern were detected (data not shown), but no 9 
differences were observed among groups; these results agree with those of other studies 10 
(Shimizu et al., 2001; Vanni et al., 2009). Methicillin-resistant staphylococci (MRS) 11 
were isolated in the present study (10.4%) in a proportion higher than that recorded in 12 
other studies (Holm et al., 2002; Rantala et al., 2004; Vanni et al., 2009). Statistical 13 
analysis showed a notable association between exposure to long-term treatments and the 14 
presence of MRS staphylococci (OR 4.6, 95% CI [1.15, 15.9]). Among the MRS 15 
isolates, resistance to other antimicrobial agents have been detected. In veterinary 16 
medicine, recent publications have also demonstrated increased prevalence of MRS 17 
resistance to fluoroquinolones, macrolides, aminoglycosides and tetracyclines (Kadlec 18 
et al., 2010). 19 
  20 
Statistical analysis to determine possible risk factors associated with the 21 
isolation of multidrug resistant (MR) and methicillin resistant (MRS), respectively 22 
(Table 4), shows that more MR staphylococci were isolated from urban than rural dogs 23 
(OR 3.79; 95% CI [1.09, 13.17]) and curiously all the MRS isolates were obtained from 24 
urban dogs. This is probably due to the greater prescription of antimicrobial agents for 25 
urban dogs and their greater use of veterinary clinics, hospitals and kennels.  Other 26 
variables studied, such as sex or treatment history, were not found to be associated with 27 
the MR or MRS characteristics of the isolates.  28 
 29 
Clindamycin has traditionally been the drug of choice for the empirical 30 
treatment of canine pyoderma, including the treatment of infections caused by MRS 31 
strains, given its good oral absorption, excellent penetration and scant secondary 32 
reactions (Faires et al., 2009). However, the high percentage of resistance detected in 33 
































microbiological analysis. In addition, there are many references referring to cross-1 
resistance between erythromycin and clindamycin (Ganiere et al., 2005) as well as a 2 
form of inducible resistance to clindamycin.  The latter is not detected in routine disc-3 
plaque diffusion tests, and can lead to therapeutic failure.  The identification of strains 4 
with inducible macrolide resistance can be achieved via double disc diffusion inhibition 5 
assays (the D-Test). A positive D-test suggests the presence of an erm gene that could 6 
result in a constitutive clindamycin resistance and potential clinical failure of this drug 7 
(Swenson et al., 2007; Yilmaz et al., 2007). If the D-test is negative, clindamycin can be 8 
used therapeutically. In the present study, 29 (27.6%) of the 105 isolates were resistant 9 
to both erythromycin and clindamycin (Fig. 1). The D-test results for 16 isolates that 10 
presented an unusual pattern in the Kirby-Bauer test (ERY-resistant but CLI-11 
susceptible) showed two isolates (11.1%), both SIG members, to possess an inducible 12 
form of clindamycin resistance. Previous studies have shown the percentage of strains 13 
showing inducible resistance to range between 12.3% (Levin et al., 2005) and 37.5% 14 
(Rich et al., 2005) in both the human and veterinary medicine settings; this resistance 15 
has been associated with strains of S. aureus and CoNS (Faires et al., 2009).  The 16 
present results suggest the D-test should be routinely performed concurrently with 17 




Staphylococcal resistance to antimicrobial agents is more pronounced in urban 22 
animals with recurrent pyoderma that have undergone long-term, empirical, 23 
antimicrobial treatment.  The susceptibility of staphylococci causing pyoderma should 24 
always be checked in vitro in order to select the best treatment. The present results 25 
suggest the routine use of the D-test to assess the effectiveness of clindamycin in the 26 
treatment of pyoderma, especially when caused by MRS strains. 27 
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Biochemical identification of the isolates
b
 
SIG S. aureus CoNS 
A (n=23) 16 (69.5) 21 (20%) 13 2 6 
B (n =24) 24 (100) 40 (38%) 34 3 3 
C (n=27) 27 (100) 44 (42%) 36 5 3 
Total (n= 74) 67 (90.5) 105 (100) 83 (79%) 10 (9.5%) 12 (11.4%) 
 4 
a 
Groups of animals (number): Group A (healthy dogs), Group B (animals with first-time pyoderma), and 5 
group C (dogs presenting with recurrent pyoderma that received long-term antibiotic treatments). 6 
b






















































Table 2.  In vitro susceptibility (disk diffusion method) of the 105 staphylococci isolates. 1 
Antimicrobial (µg/disk) 
No. of resistant isolates (%) 
Total  Group A
a
 Group B Group C 
Ampicillin (10 µg/disk) 72 (68.6%) 12 (57.1%) 29 (72.5%) 31 (70.5%) 
Amoxicillin-clavulanate (20 and 10 µg/disk) 11 (10.5%) - 3 (7.5%) 8 (18.2%) 
Cefadroxil (30 µg/disk) 11 (10.5%) - 3 (7.5%) 8 (18.2%) 
Ceftiofur (30 µg/disk). 11 (10.5%) - 3 (7.5%) 8 (18.2%) 
Cephalothin (30 µg/disk) 11 (10.5%) - 3 (7.5%) 8 (18.2%) 
Cephalexin (30 µg/disk) 11 (10.5%) - 3 (7.5%) 8 (18.2%) 
Oxacillin
b
 11 (10.5%) - 3 (7.5%) 8 (18.2%) 
Gentamicin (10 µg/disk) 4 (3.8%) - 1 (2.5%) 3 (6.8%) 
Tetracycline (30 µg/disk) 43 (41%) 4 (19%) 19 (47.5%) 20 (45.5%) 
Ciprofloxacin (5 µg/disk) 5 (4.8%) - - 5 (11.4%) 
Enrofloxacin (5 µg/disk) 7 (6.7%) 1 (4.8%) - 6 (13.6%) 
Clindamycin  (2 µg/disk) 30 (28.6%) 7 (33.3%) 10 (25%) 13 (29.5%) 
Erythromycin (15 µg/disk) 37 (35.2%) 8 (38.1%) 13 (32.5%) 16 (36.4%) 
Rifampin (5 µg/disk) 2 (1.9%) - - 2 (4.5%) 
TOTAL 105 21 40 44 
 2 
a 
Groups of animals: Group A (healthy dogs), Group B (animals with first-time pyoderma), and group C 3 
(dogs presenting with recurrent pyoderma that received long-term antibiotic treatments). 4 
b 












































Table 3.  Resistance pattern detected among the 105 staphylococci isolates analysed. 1 
RESISTANCE PATTERN 
No. OF ISOLATES (%) 
Total 
n = 105 
Group A
a 
n = 21 
Group B 
n = 40 
Group C 
n = 44 
     
Susceptible to all the antimicrobial agents 23 (21.9%) 7 (33.3%) 10 (27%) 6 (16.6%) 
Resistant to 1 or more antimicrobial agents 82 (78.1%) 14 (66.6%) 30 (75%) 38 (86.4%) 
     
Methicillin susceptible (MSS) 94 (89.5%) 21 37 36 
Resistant to 1 antimicrobial agent 25 (26.5%) 5 (23.8%) 10 (27%) 10 (27.7%) 
Resistant to 2 antimicrobial agents 17 (18.0%) 3 (14.2%) 5 (13.5%) 9 (25%) 
Resistant to 3 or more antimicrobial agents 29 (30.8%) 6 (28.5%) 12 (32.4%) 11 (30.5%) 
     
Methicillin resistant (MRS) 11 (10.4%) 0 3  8 
Resistant only to oxacillin 3 (27.3%) 0 1 (33.3%) 2 (25%) 
Resistant to 2 antimicrobial agents 3 (27.3%) 0 1 (33.3%) 2 (25%) 
Resistant to 3 or plus antimicrobial agents 5 (45.4%) 0 1 (33.3%) 4 (50%) 
 2 
a 
Groups of animals: Group A (healthy dogs), Group B (animals with first-time pyoderma), and group C 3 
(dogs presenting with recurrent pyoderma that received long-term antibiotic treatments). 4 
b
Antimicrobial abbreviations: Amp: Ampicillin; Cip: Ciprofloxacin; Enr: Enrofloxacin; E: Erythromycin; 5 
Da: Clindamycin; Te: Tetracycline; Cn: Gentamicin; Trimethoprim-sulphamethoxazole; Rd: Rifampin  6 
c
Isolates with resistance to three or more classes of antimicrobial agents were considered multiresistant 7 



























































Table 4. Study of risk factors for multiresistance (MR) and methicillin-resistance (MRS) of 3 
staphylococci isolated.  4 
 5 
Risk factors associated to multiresistance (MR) 








0.2 - - 
Age 
< 5 years (n=50) 16 (32%) 
1 - - >5  years (n=47) 15 (32%) 
No item (n=8)  
Habitat 
Urban (n=80) 31 (38.7%) 
0.03 3.79 [1.09, 13.17] Rural (n=21) 3 (14.3%) 
No item (n=4)  
Cohabitation with 
other dogs 
Yes (n=30) 7 (23.3%) 
0.24 
  
No (n=70) 26 (37.1%) - - 
No item (n=5)    
Treatment 
Yes (n=44) 15 (34%) 
0.75 - - 
No (n=61) 19 (31.1%) 
Risk factors associated to methicillin resistance (MRS) 








0.07 - - 
Age 
< 5 years (n=50) 4 (8%) 
0.74 - - >5  years (n=47) 5 (10.6%) 
No item (n=8)  
Habitat 
Urban (n=80) 9 (11.2%) 
0.19 - - Rural (n=21) 0 (0%) 
No item (n=4)  
Cohabitation with 
other dogs 
Yes (n=30) 3 (10%) 
1 
  
No (n=70) 6 (8.5%) - - 
No item (n=5)    
Treatment 
Yes (n=44) 8 (18.2%) 
0.04 4.3 [1.15, 15.9] 
No (n=61) 3 (5%) 
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